Haixin Group Co., Ltd. are a mainly on fake fur /
plush products production and management, and have already exploit to medicinal
industry and financial field development, A / B-share listed company.
Predecessor (Sino-foreign joint venture) Shanghai Haixin Co., Ltd., was
established in 1986, has changed to the joint-stock company in 1993. In
December 1993 and April 1994, B-share and A-share were listed in shanghai stock
exchange. It is now one of the 180 index sample.
Now, total shares is about 600 million among which there are about 200 million
shares of B-shares and about 180 million shares of A-shares. Total assets are
about 3,300 million yuan (RMB) and net assets are about 1,800 million yuan
The company imports the raw materials from Japan and is engaged in the research
and development of plush fabrics, acrylic yarn and polyester fiber, stuffed
toys, acrylic blanket, garments etc. and chemical raw materials medicine of
processing and manufacturing, biologicals, health products, traditional Chinese
raw materials medicine and preparations all kinds of, etc., and engaged in the
investment business of the national industrial policy and assets management and
The enterprises accelerate the optimization resource distribution paces in the
world in 2002, has succeeded in purchasing the textile subsection of US GLENOIT
Company with history of 70 years and have got 46 brand trade mark that can use
for ever and then it become a world plush produce giants from a big pile
enterprise in Asia, account for 60% of fake fur garments market of North
America and Canada. For this reason, our annual production capacity of
imitation fur fabric has already reached 40 million meters.
Our fake fur / plush fabrics has guided the domestic leading enterprise on the
consumer market. Design the pluralism of disposing, the large-scale
transnational enterprise is becoming with global and integrated marketing, and
plan to set up the manufacturing enterprise of fake fur garments with greater
economic scale rapidly and form a brand product production base that from plush
fabrics to garments sell.
In medicinal field, Shanghai Haixin Group Co., Ltd. has already put into about
200 million yuan (RMB), to set up Haixin biotechnology and Xi'an Huahao
Jingying two medicinal research and development companies. Haixin has invest
and build up Xi'an Haixin Pharmaceutical Co., Ltd., Jiangsu Suzhong Haixin
Pharmaceutical Co., Ltd. and Jiangxi Gannan Haixin Pharmaceutical Co., Ltd.
three medicinal manufacturing enterprises. Haixin has also invest Jiangsu
Suzhong Haixin Pharmaceutical Co., Ltd. and Shanghai Yan'an Wanxiang
Pharmaceutical Co., Ltd., and Shanghai biotechnology industrialized area
Medicinal sale limited company. And then it have formed a trinity medicinal
industry combined with research production and sale.
In financial investment, Shanghai Haixin Group Co., Ltd. invests 230 million
yuan (RMB) to the Changjiang Securities Company, account for registered capital
2000 million yuan (RMB) of 10% after adding it. Shanghai Haixin Group Co.,
Ltd., Changjiang Securities Company and Wuhan Steel Processing Co., Ltd. set up
together Changxin Asset Management Corporation Limited in May 2003, registered
capital is 90 million yuan (RMB), among which Shanghai Haixin Group Co., Ltd.
accounts for 34.33%.
The goal in the future of the enterprise: Keep the lasting steady-state growth
of the business performance, Expand the scale of textile industry and
occupation rate of market further, accelerate adjusting the industrial
structure of company, improving has considerable profit of garment of imitation
fur fabrics, development and expands the industry of fake fur garments, make it
become new important point of growth of profit. According to the real and
demand for development which the company trade manages, improve the managerial
ability and cultural intension of the enterprise. Probe different trades and
areas internationalized management mode of group enterprise. Keep steady growth
in managing business income and net profit mainly. In the following five years,
enterprise development scale rise to 3 billion yuan (RMB) from 1,800 million
yuan (RMB) of net assets. Annual net total profit rise to 350 million yuan
(RMB) from 157 million yuan (RMB), establishing high-grade textile products,
biological medicine and financial investment pluralistic industry of the
Trinity develop pattern.